|
業務類別
|
Biotechnology |
|
業務概覽
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body. |
| 公司地址
| 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130 |
| 電話號碼
| +1 888 969-7879 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.travere.com |
| 員工數量
| 497 |
| Ms. Elizabeth E. Reed |
Chief Legal Officer, General Counsel and Corporate Secretary |
-- |
01/04/2025 |
| Dr. William E. Rote, PhD |
Chief Research Officer |
美元 502.83K |
01/04/2025 |
| Dr. Eric M. Dube, PhD |
Director, President and Chief Executive Officer |
美元 822.00K |
19/02/2026 |
| Mr. Peter Heerma |
Chief Commercial Officer |
美元 503.75K |
01/04/2025 |
| Dr. Jula Inrig, M.D. |
Chief Medical Officer |
美元 522.08K |
01/04/2025 |
| Mr. Christopher Cline |
Chief Financial Officer |
美元 497.50K |
19/02/2026 |
| Ms. Sandra Calvin |
Senior Vice President and Chief Accounting Officer |
-- |
19/02/2026 |
|
|
| Mr. Gary A. Lyons |
Chairman of the Board |
19/02/2026 |
| Mr. Ron Squarer |
Independent Director |
19/02/2026 |
| Mr. Timothy P. Coughlin |
Independent Director |
19/02/2026 |
| Mr. John A. Orwin, M.B.A. |
Independent Director |
19/02/2026 |
| Dr. Suzanne L. Bruhn, PhD |
Independent Director |
19/02/2026 |
| Mr. Jeffrey A. Meckler |
Independent Director |
19/02/2026 |
| Ms. Sandra E. Poole |
Independent Director |
19/02/2026 |
| Dr. Roy D. Baynes, M.D.,PhD |
Independent Director |
19/02/2026 |
| Dr. Eric M. Dube, PhD |
Director, President and Chief Executive Officer |
19/02/2026 |
| Ms. Ruth Williams-Brinkley |
Independent Director |
19/02/2026 |
|
|
|
|
